Visual Abstract - A Cell-Enriched Engineered Myocardial Graft Limits Infarct Size and Improves Cardiac Function: Pre-Clinical Study in the Porcine Myocardial Infarction Model: 10.1016/j.jacbts.2016.06.005

• MI remains a major cause of morbidity and mortality despite major treatment advances achieved during the past decades.

• Administration of an engineered myocardial graft, composed of decellularized myocardial matrix refilled with ATDPCs (EMG-ATDPC), in a porcine pre-clinical MI model, may support cardiac recovery following MI.

• Thirty days post-EMG-ATDPC implantation, cardiac magnetic resonance imaging and comprehensive histological analysis were performed to evaluate its impact on myocardial restoration.

• EMG-ATDPC resulted in better left ventricular ejection fraction, higher vessel density and neovascularization, and reduced infarct size by 68%, as well as limited fibrosis.

• Accordingly, EMG-ATDPC is ready to start the translational avenue toward phase I first-in-man clinical trials.